Fosaprepitant

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

34 Suppliers, 16 USDMF, 3 JDMF, 6 EU WC, 3 KDMF, 12 NDC API, 23 Listed Suppliers

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

3 Suppliers

3 Suppliers

DOSSIERs // Finished Dosage Forms

44 Dossiers, 24 FDA Orange Book, 4 Europe, 1 Canada, 6 Australia, 1 South Africa, 8 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers, 7 Kerry, 6 Seppic, 3 Actylis, 3 Gangwal Chemicals, 2 Nanjing Well Pharmaceutical, 1 Microlex e.U, 1 Nanjing Bold Chemical, 1 BASF, 1 DFE Pharma, 1 Jai Radhe Sales

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 7 Parenteral, 5 Fillers, Diluents & Binders, 3 Topical, 3 Co-Processed Excipients, 3 Direct Compression, 3 Emulsifying Agents, 2 Surfactant & Foaming Agents, 1 Film Formers & Plasticizers, 1 Granulation, 1 Rheology Modifiers, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

GLOBAL SALES INFORMATION

33 US Medicaid Prescriptions, 2 Finished Drug Prices

MARKET PLACE

1 DOSSIERS // FDF

1 DOSSIERS // FDF

PATENTS

1 US Patents, 2 US Exclusivities, 2 Health Canada Patents

DIGITAL CONTENT

30 News

30 News

Information, Expiry & Status of Health Canada Patents covering Fosaprepitant.

Fosaprepitant

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

34 Suppliers

16 USDMF

3 JDMF

6 EU WC

3 KDMF

12 NDC API

23 Listed Suppliers

DEVELOPMENTS

3 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

3 Suppliers

DOSSIERs // Finished Dosage Forms

44 Dossiers

24 FDA Orange Book

4 Europe

1 Canada

6 Australia

1 South Africa

8 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers

7 Kerry

6 Seppic

3 Actylis

3 Gangwal Chemicals

2 Nanjing Well Pharmaceutical

1 Microlex e.U

1 Nanjing Bold Chemical

1 BASF

1 DFE Pharma

1 Jai Radhe Sales

EXCIPIENTS BY APPLICATIONS

10 Solubilizers

7 Parenteral

5 Fillers, Diluents & Binders

3 Topical

3 Co-Processed Excipients

3 Direct Compression

3 Emulsifying Agents

2 Surfactant & Foaming Agents

1 Film Formers & Plasticizers

1 Granulation

1 Rheology Modifiers

1 API Stability Enhancers

1 Thickeners and Stabilizers

GLOBAL SALES INFORMATION

33 US Medicaid Prescriptions

2 Finished Drug Prices

MARKET PLACE

1 DOSSIERS // FDF

PATENTS

1 US Patents

2 US Exclusivities

2 Health Canada Patents

DIGITAL CONTENT

30 News

Fosaprepitant

Merck Frosst Canada Ltd

Fosaprepitant

2183250

115 mg/vial

Lyophilized powder

Human

2015-02-28

2006-03-21

1995-02-28

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons